Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 14INDUSTRY 2NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Cryopyrin-Associated Periodic Syndromes 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT03430011 2024-05-24

EVOLVE

Juno Therapeutics, a Subsidiary of Celgene

Phase 1/2 Completed
165 enrolled 38 charts
Plasma cell

Multiple Myeloma

NCT02326376 2020-01-18

Kineret CAPS Post Authorisation Study

Swedish Orphan Biovitrum

Completed
12 enrolled

Cryopyrin-Associated Periodic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡